MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, RAPP had -$169,143K decrease in cash & cash equivalents over the period. $50,072K in free cash flow.

Cash Flow Overview

Change in Cash
-$169,143K
Free Cash flow
$50,072K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Purchases of short-term investme...
    • Net loss
    • Sale of short-term investments
    • Others
Negative Cash Flow Breakdown
    • Maturities of short-term investm...
    • Accrued expenses and other curre...
    • Non-cash lease expense
    • Others

Cash Flow
2026-03-31
2025-09-30
2025-06-30
Net loss
57,863 -26,925 -50,795
Depreciation and amortization
-525 256 496
Non-cash loss on sale of property and equipment
153 --
Net (accretion) and amortization of investments in marketable securities
40 -204 528
Non-cash lease expense
-879 567 894
Stock-based compensation expense
-6,201 4,735 8,429
Accounts receivable
58 --
Prepaid expenses and other current assets
-3,424 -2,534 5,144
Other assets
-1,256 362 548
Accounts payable
1,268 -179 1,216
Accrued expenses and other current liabilities
-5,971 1,696 784
Operating lease liabilities
579 -9 111
Net cash used in operating activities
49,711 -17,465 -45,307
Purchases of short-term investments
-127,343 101,620 56,093
Sale of short-term investments
10,075 --
Maturities of short-term investments
-86,689 44,978 100,033
Purchases of property and equipment
-361 134 313
Net cash provided by investing activities
51,090 -56,776 43,627
Proceeds from underwritten public offering, net of underwriter discounts and commissions and deferred offering costs
-269,834 -
Payment of deferred offering costs
210 -63
Proceeds from exercise of stock options
167 636 6
Repurchase of unvested restricted common stock
4 0 1
Net cash provided by financing activities
-269,944 270,533 -58
Net increase in cash, cash equivalents, and restricted cash
-169,143 196,292 -1,738
Cash, cash equivalents, and restricted cash at beginning of period
251,464 56,910 -
Cash, cash equivalents, and restricted cash at end of period
78,161 251,464 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Purchases of short-terminvestments-$127,343K Net loss$57,863K Sale of short-terminvestments$10,075K Purchases of property andequipment-$361K Prepaid expenses andother current assets-$3,424K Accounts payable$1,268K Other assets-$1,256K Non-cash loss on sale ofproperty and equipment$153K Net cash provided byinvesting activities$51,090K Net cash used inoperating activities$49,711K Canceled cashflow$86,689K Canceled cashflow$14,253K Net increase incash, cash...-$169,143K Canceled cashflow$100,801K Proceeds from exercise ofstock options$167K Maturities of short-terminvestments-$86,689K Stock-based compensationexpense-$6,201K Accrued expenses andother current...-$5,971K Non-cash lease expense-$879K Operating leaseliabilities$579K Depreciation andamortization-$525K Accounts receivable$58K Net (accretion) andamortization of investments...$40K Net cash provided byfinancing activities-$269,944K Canceled cashflow$167K something is missing-$269,897K Payment of deferredoffering costs$210K Repurchase of unvestedrestricted common stock$4K

Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics, Inc. (RAPP)